Takeda already has one shot in Huntington’s, via a 2018 deal with Wave Life Sciences. The Japanese company put down another marker in the disease today by teaming up with the private Israeli company Anima Biotech, in a transaction worth $120m up front.
Anima’s approach is intriguing, but early: the group develops small molecules designed to control mRNA translation, with the ultimate goal of either increasing or decreasing levels of a target protein. In the case of its preclinical Huntington’s project the aim is to decrease translation of the mutant huntingtin (HTT) protein without affecting the wild-type protein.
In this way, Anima’s approach is similar to that from Wave, though Wave uses not small molecules but antisense oligonucleotides. If Anima ultimately succeeds, its small-molecule approach could have cost and convenience advantages over Wave’s projects and other antisense candidates in development, such as Roche and Ionis’s tominersen.
However, proof of concept is still some way away: Anima’s Huntington’s asset is not set to reach the clinic for another three to four years, the company’s chief executive, Yochi Slonim, told Evaluate Vantage.
At least now the smaller group will have Takeda’s help to get there. The partnership is quite unusual in that the Japanese giant is contributing to preclinical development. “Many deals aren’t true collaborations – they don’t really get the pharma involved in the research in the way Anima is looking to do,” Mr Slonim said.
If the project does make it to the clinic Takeda will then take it forward.
According to Mr Slonim, Anima’s Huntington’s project had drawn interest from multiple potential partners, but the company chose Takeda for its “breadth of expertise” in the disease.
Could the Anima deal mean that Takeda’s enthusiasm for Wave’s assets has cooled? Mr Slonim does not think so: “Takeda is setting itself up to be the leader in this field, and I think it wants to have many strategies.”
In any case, this quarter will see more data from Wave that could determine whether Takeda opts into its projects.
Meanwhile, Takeda’s deal with Anima, which could be worth up to $2.4bn in total, also covers two more undisclosed targets in neurology; Mr Slonim would not give more details, but said the focus would be on genetically defined disorders.
And Takeda has an option to broaden the collaboration with up to three more unnamed targets, also in neurology.
One thing is clear: Anima's Tau-targeting Alzheimer's project is not covered by the agreement.
The latest collaboration adds to a 2018 agreement between Anima and Lilly, for which the Israeli group received $30m up front, covering undisclosed targets in neuroscience.
|The Huntington's disease landscape|
|Project||Company||Description||Status||2026e indication sales ($m)|
|VX15||Vaccinex||Semaphorin 4D antibody||Phase II Signal study failed in Sep 2020 but development continues||1,091*|
|Tominersen||Roche/Ionis||Huntingtin antisense oligonucleotide||Phase III Generation HD1 trial to read out 2022||546|
|AMT-130||Uniqure||MicroRNA targeting huntingtin gene||Phase I/II, initial data due YE 2021||282|
|WVE-120101||Wave Life Sciences||Stereopure huntingtin antisense oligonucleotide||Phase I/II Precision-HD1 data due Q1 2021||239|
|WVE-120102||Wave Life Sciences||Stereopure huntingtin antisense oligonucleotide||Phase I/II Precision-HD2 data due Q1 2021||179|
|*Most forecasts made before Signal trial failure. Source: EvaluatePharma.|